Mostrando 2 resultados de: 2
Low-Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy the ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)
Conference ObjectAbstract: Background and Purpose'Many patients receiving thrombolysis for acute ischemic stroke are on prior aPalabras claves:aspirin, Brain Infarction, Hypertension, intracranial hemorrhages, Tissue plasminogen activatorAutores:Arima H., Bath P.M.W., Billot L., Broderick J.P., Chalmers J., Demchuk A.M., Donnan G.A., Kim J.S., Lavados P.M., Lee T.H., Lindley R.I., Martins S.O., Nguyen T.H., Octavio Marques Pontes-Neto, Olavarria V.V., Pandian J.D., Parsons M.W., Ricci S., Robinson T.G., S Anderson C., Sato S., Sharma V.K., Wang J.G., Wang X., Woodward M.Fuentes:scopusLow-dose vs standard-dose alteplase for patients with acute ischemic stroke: Secondary analysis of the ENCHANTED randomized clinical trial
ArticleAbstract: IMPORTANCE: A lower dose of intravenous alteplase appears to be a safer treatment option than the stPalabras claves:Autores:Arima H., Bath P.M.W., Billot L., Broderick J.P., Chalmers J., Demchuk A.M., Donnan G.A., Kim J.S., Lavados P.M., Lee T.H., Li Q., Lindley R.I., Martins S.O., Octavio Marques Pontes-Neto, Olavarria V.V., Pandian J.D., Parsons M.W., Ricci S., Robinson T.G., S Anderson C., Sharma V.K., Thang N.H., Wang J.G., Wang X., Woodward M.Fuentes:scopus